- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Oncology Experts Preview Top Abstracts to be Shared at 2025 ASCO GI
January 22nd 2025, 11:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
Tanios S. Bekaii-Saab, MD, and Yelena Y. Janjigian, MD, preview top presentations from this year’s Gastrointestinal Cancers Symposium.
Everolimus Plus Lanreotide Extends PFS in Advanced GEP-NETs
January 21st 2025, 10:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
Everolimus plus lanreotide demonstrated an improved PFS compared with everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
Nivolumab Plus Gemcitabine/Cisplatin Shows Favorable OS/PFS Trend in Asian Unresectable/Metastatic Urothelial Cancer Subpopulation
January 15th 2025, 3:06pm
First-line nivolumab plus chemotherapy numerically improved survival vs chemotherapy alone in Asian patients with unresectable/metastatic urothelial cancer.
Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC
January 9th 2025, 1:00pm
Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.
Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
January 6th 2025, 1:00pm
First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.
BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy
January 4th 2025, 11:00am
BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.
Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer
January 3rd 2025, 2:00pm
Tremelimumab plus paclitaxel induced responses in metastatic urothelial cancer after progression on platinum and an immune checkpoint inhibitor.
Pembrolizumab Plus SBRT Fails to Improve Survival in Unresected Stage I/II NSCLC
January 2nd 2025, 9:00pm
The addition of pembrolizumab to radiation did not improve survival in unresected, stage I or II non–small cell lung cancer.
T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC
December 30th 2024, 3:00pm
Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
December 23rd 2024, 2:00pm
CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
December 21st 2024, 11:00am
The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
December 20th 2024, 1:00pm
Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
December 19th 2024, 7:00pm
Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
December 19th 2024, 6:00pm
The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS
December 17th 2024, 1:00pm
San Antonio Breast Cancer Symposium
Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care.
Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer
December 16th 2024, 2:00pm
San Antonio Breast Cancer Symposium
Radiation therapy produced superior HRQOL outcomes and fewer toxicities vs endocrine therapy in older patients with stage I luminal-like breast cancer.
Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer
December 16th 2024, 1:00pm
San Antonio Breast Cancer Symposium
Ultra-sensitive tissue-free ctDNA testing showed that baseline ctDNA was associated with larger pathological tumor size in HR-positive breast cancer.
Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer
December 15th 2024, 11:00am
San Antonio Breast Cancer Symposium
Elacestrant increased real-world TTNT for patients with ESR1-mutant HR-positive/HER2-negative breast cancer vs PFS from the phase 3 EMERALD trial.
ICIs Result in Increased Rates of High-Grade irAEs for Older Patients With Breast Cancer
December 14th 2024, 11:00am
San Antonio Breast Cancer Symposium
The risk of developing high-grade immune-related AEs was heightened among patients with breast cancer who were older and who had chronic kidney disease.
Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer
December 14th 2024, 12:25am
San Antonio Breast Cancer Symposium
Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.